Santhera Pharmaceuticals Holding AG (SANNZ.XC)
Cboe UK · CHF · Healthcare · Biotechnology
CHF 14.86 (+4.71%) as of
Key statistics
- Market cap
- 208.87M
- EPS (TTM)
- -2.24
- Dividend yield
- 0.00%
- 52-week range
- 10.08 – 18.80
- Beta
- -0.39
- Revenue (TTM)
- 101.5M
- Profit margin
- -31.46%
- Volume
- 874.00
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Pratteln, Switzerland
- Employees
- 93
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.